SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-4/A - Registration of securities, business combinations: [Amend]
SEC Accession No. 0001213900-22-020222
Filing Date
2022-04-18
Accepted
2022-04-15 17:37:58
Documents
161

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT fs42022a2_biotechacq.htm   iXBRL S-4/A 14738184
2 OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP fs42022a2ex5-1_biotechacq.htm EX-5.1 23788
3 TAX OPINION OF ELLENOFF GROSSMAN & SCHOLE LLP fs42022a2ex8-1_biotechacq.htm EX-8.1 11524
4 OFFER LETTER, DATED AS OF JULY 18, 2016, BY AND BETWEEN BLADE THERAUEPTICS, INC. fs42022a2ex10-15_biotechacq.htm EX-10.15 30977
5 OFFER LETTER, DATED AS OF FEBRUARY 1, 2021, BY AND BETWEEN BLADE THERAPEUTICS, I fs42022a2ex10-16_biotechacq.htm EX-10.16 24351
6 OFFER LETTER, DATED AS OF APRIL 19, 2017, BY AND BETWEEN BLADE THERAPEUTICS, INC fs42022a2ex10-17_biotechacq.htm EX-10.17 15566
7 OFFER LETTER, DATED AS OF SEPTEMBER 30, 2016, BY AND BETWEEN BLADE THERAPEUTICS, fs42022a2ex10-18_biotechacq.htm EX-10.18 23083
8 AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT fs42022a2ex10-19_biotechacq.htm EX-10.19 13219
9 AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT fs42022a2ex10-20_biotechacq.htm EX-10.20 12471
10 AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT fs42022a2ex10-21_biotechacq.htm EX-10.21 12413
11 AMENDMENT TO OFFER LETTER, DATED AS OF MARCH 24, 2022, BY AND BETWEEN BLADE BIOT fs42022a2ex10-22_biotechacq.htm EX-10.22 13264
12 CONSENT OF MARCUM LLP fs42022a2ex23-1_biotechacq.htm EX-23.1 2566
13 CONSENT OF ERNST AND YOUNG LLP, INDEPENDENT REGISTERED ACCOUNTING FIRM FOR BLADE fs42022a2ex23-2_biotechacq.htm EX-23.2 1917
14 CONSENT OF WENDYE ROBBINS TO BE NAMED AS A DIRECTOR fs42022a2ex99-2_biotechacq.htm EX-99.2 2781
15 CONSENT OF MARK TIMNEY TO BE NAMED AS A DIRECTOR fs42022a2ex99-3_biotechacq.htm EX-99.3 2756
16 CONSENT OF LLOYD KLICKSTEIN TO BE NAMED AS A DIRECTOR fs42022a2ex99-4_biotechacq.htm EX-99.4 2692
17 CONSENT OF JAMES SCOPA TO BE NAMED AS A DIRECTOR fs42022a2ex99-5_biotechacq.htm EX-99.5 2752
18 CONSENT OF LUKE EVNIN TO BE NAMED AS A DIRECTOR fs42022a2ex99-6_biotechacq.htm EX-99.6 2753
19 CONSENT OF JOHN A. HOHNEKER, M.D. TO BE NAMED AS A DIRECTOR fs42022a2ex99-7_biotechacq.htm EX-99.7 2793
20 CONSENT OF CARL GOLDFISCHER, M.D. TO BE NAMED AS A DIRECTOR fs42022a2ex99-8_biotechacq.htm EX-99.8 2830
21 GRAPHIC ex10-15_001.jpg GRAPHIC 8891
22 GRAPHIC ex10-16_001.jpg GRAPHIC 3598
23 GRAPHIC ex10-17_001.jpg GRAPHIC 3600
24 GRAPHIC ex10-18_001.jpg GRAPHIC 14480
25 GRAPHIC ex10-19_001.jpg GRAPHIC 7447
26 GRAPHIC ex10-19_002.jpg GRAPHIC 6620
27 GRAPHIC ex10-20_001.jpg GRAPHIC 7447
28 GRAPHIC ex10-20_002.jpg GRAPHIC 6620
29 GRAPHIC ex10-21_001.jpg GRAPHIC 7447
30 GRAPHIC ex10-21_002.jpg GRAPHIC 6620
31 GRAPHIC ex10-22_001.jpg GRAPHIC 7447
32 GRAPHIC ex10-22_002.jpg GRAPHIC 6620
33 GRAPHIC timage_001.jpg GRAPHIC 332585
34 GRAPHIC timage_002.jpg GRAPHIC 497065
35 GRAPHIC timage_003.jpg GRAPHIC 234595
36 GRAPHIC timage_004.jpg GRAPHIC 236924
37 GRAPHIC timage_005.jpg GRAPHIC 281576
38 GRAPHIC timage_008.jpg GRAPHIC 634866
39 GRAPHIC timage_009.jpg GRAPHIC 456998
40 GRAPHIC timage_010.jpg GRAPHIC 202698
41 GRAPHIC timage_011.jpg GRAPHIC 366569
42 GRAPHIC timage_012.jpg GRAPHIC 523511
43 GRAPHIC timage_013.jpg GRAPHIC 651939
44 GRAPHIC timage_014.jpg GRAPHIC 402930
45 GRAPHIC timage_015.jpg GRAPHIC 394241
46 GRAPHIC timage_016.jpg GRAPHIC 613108
47 GRAPHIC timage_017.jpg GRAPHIC 506892
48 GRAPHIC timage_018.jpg GRAPHIC 307049
49 GRAPHIC timage_019.jpg GRAPHIC 408186
50 GRAPHIC timage_020.jpg GRAPHIC 548620
51 GRAPHIC timage_021.jpg GRAPHIC 540532
52 GRAPHIC timage_022.jpg GRAPHIC 544084
53 GRAPHIC timage_023.jpg GRAPHIC 581089
54 GRAPHIC timage_024.jpg GRAPHIC 472248
55 GRAPHIC tvantage_header.jpg GRAPHIC 253198
56 GRAPHIC tvantage_footer1.jpg GRAPHIC 44525
57 GRAPHIC tvantage_footer11.jpg GRAPHIC 44525
58 GRAPHIC tvantage_sig.jpg GRAPHIC 57696
  Complete submission text file 0001213900-22-020222.txt   52881894

Data Files

Seq Description Document Type Size
59 XBRL SCHEMA FILE biot-20211231.xsd EX-101.SCH 143802
60 XBRL CALCULATION FILE biot-20211231_cal.xml EX-101.CAL 44256
61 XBRL DEFINITION FILE biot-20211231_def.xml EX-101.DEF 618246
62 XBRL LABEL FILE biot-20211231_lab.xml EX-101.LAB 961200
63 XBRL PRESENTATION FILE biot-20211231_pre.xml EX-101.PRE 608243
155 EXTRACTED XBRL INSTANCE DOCUMENT fs42022a2_biotechacq_htm.xml XML 3468884
Mailing Address 545 WEST 25TH STREET 20TH FLOOR NEW YORK NY 10001
Business Address 545 WEST 25TH STREET 20TH FLOOR NEW YORK NY 10001 8586920539
Biotech Acquisition Co (Filer) CIK: 0001825413 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: S-4/A | Act: 33 | File No.: 333-263577 | Film No.: 22830736
SIC: 2834 Pharmaceutical Preparations